FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Voyager Therapeutics, Inc. on the Rise after announcing license option deal with Pfizer”
Voyager Therapeutics, Inc. (NASDAQ: VYGR) surged over 61% in premarket trading after the company announced a license option agreement with Pfizer for next-generation TRACERᵀᴹ AAV Capsids.
Through the agreement, Pfizer Inc may exercise options to license novel capsids generated from Voyager’s RNA-driven TRACER screening technology and Voyager receives $30 million up front with potential option exercise fees and milestone payments of up to $600 million plus product sales-based royalties.
Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the technology to treat devastating diseases. Proprietary capsids born from the Company’s TRACER screening platform are powering a rich early-stage pipeline of new and second-generation programs and may elevate the field to overcome the limitations of conventional gene therapy vectors across neurologic disorders and other therapeutic areas.
For more information, please visit: Voyager Therapeutics, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.